En Carta Diagnostics Secures €5 Million to Revolutionize At-Home Molecular Testing
En Carta Diagnostics, a pioneering DeepTech startup based in Paris, has announced a successful fundraising round, securing €5 million to advance the development of its novel at-home molecular diagnostics technology.
Investment and Strategic Partnerships
The funding comprises €3 million in equity led by Blue Forest Ventures, with participation from Ring Capital and returning investors such as CentraleSupélec Venture, 50 Partners Health, and a consortium of business angels. Additionally, €2 million was obtained through non-dilutive financing from Bpifrance and associated partners. This follows a pre-seed funding round of €1.5 million secured in May 2024, spearheaded by CentraleSupélec Venture.
Transforming Access to Diagnostics
“This first close brings us closer to our mission to transform access to testing. By enabling reliable molecular testing for patients wherever they are, we can drive earlier diagnosis, improve patient outcomes, and help ease pressure on healthcare systems,” said Guillaume Horréard, co-founder and CEO of En Carta Diagnostics.
Innovative Diagnostic Solutions
Founded in 2022 by Horréard and Margot Karlikow, En Carta Diagnostics is on a mission to redefine at-home testing by merging the accuracy of laboratory PCR diagnostics with the ease of rapid tests. The company’s proprietary platform is designed to deliver high-performance molecular diagnostics directly to patients, bypassing the need for traditional lab infrastructure.
Focus on Lyme Disease and Beyond
The startup is intensifying its efforts to combat Lyme disease, a rampant vector-borne illness in the Northern Hemisphere, affecting 1.2 million individuals annually. The disease’s incidence is escalating at a notable rate of 22.5% per year, according to the CDC. En Carta’s molecular diagnostic product aims to deliver results within 30 minutes at home, combining ease and precision.
Advancing Diagnostic Technology
The company highlights its rapid point-of-need molecular diagnostic platform, presented in an affordable cassette format. This platform uses aptamers capable of binding with high affinity and specificity to predetermined targets, allowing detection of various genetic, pathogenic, or veterinary indications.
Market Expansion and Clinical Trials
En Carta is focusing on the commercialization of its technology, beginning with Lyme disease detection and expanding into STI screening. The company has completed its initial human trials and is conducting two clinical trials in Boston, USA, and Bialystock, Poland, for early Lyme disease detection.
Regulatory Advancements and Partnerships
In January 2026, En Carta received the FDA Breakthrough Device designation, facilitating an expedited regulatory pathway to the U.S. market. Furthermore, the company has entered a co-development and marketing agreement with AAZ, a French leader in self-tests and rapid diagnostic tests. This €13 million partnership aims to commercialize new rapid molecular tests for chlamydia and gonorrhea in Europe over five years.
Future Prospects
“From FDA Breakthrough Designation to a €13 million commercial partnership, and now €5 million in funding, En Carta is delivering on its promises. Our next step is to put our two products, a rapid molecular diagnostic for Borrelia, the bacteria that causes Lyme disease, and an STI screening test, into the hands of patients and clinicians across Europe and the United States,” added Horréard.
With this funding, En Carta plans to advance regulatory certification of its molecular testing solutions in Europe and the United States, supported by its recent Breakthrough Device designation. They aim to accelerate large-scale industrialization through a fabless model in partnership with Circum Medical, ensuring cost-effective, high-volume manufacturing.
Ultimately, the goal is to expedite the commercial launch and market expansion, starting with Lyme disease detection and proceeding to additional applications like STI screening.
“`
